Nu Skin Enterprises, Inc.: stock overview

NUSNYSEHealthcare · Wholesale-Drugs, Proprietaries & Druggists' Sundries

Price

$4.03

November 13, 2026Market cap $194M

DCF calculator

What Ploutos Investor adds for Nu Skin Enterprises

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Nu Skin Enterprises had revenue of $1.3B over the last 12 months and a net loss of $234M. Revenue fell by 10.5% a year on average over the last 5 years. It has net debt of $45M. It pays a dividend yielding 5.99%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$194M
48.13M shares
P/E
–
median of 3 years: 17.7
Revenue, 12 months
$1.3B
-10.5% a year over 5 years
Net margin
-17.7%
2025: 10.8%, above 96% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-13.2% a year over 2 years

  • 202510-K
    Revenue$1.5B
  • 202410-K
    Revenue$1.7B
  • 202310-K
    Revenue$2.0B

Fiscal years in figures

NUS's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $463M
$194M
Enterprise value 
$239M
P/E 
–
EV / EBIT 
–
EV / Revenue 
0.2
P/B 3-year median: 0.6
0.4
FCF yield 3-year median: 9.9%
–
Earnings yield 3-year median: 0.9%
–

Profitability

Gross margin 
67.8%
Operating margin 
-2.0%
Net margin 3-year median: 0.4%
-17.7%
ROIC 
-2.3%
ROIC, 5-year average 
3.5%
ROE 
-33.6%

Growth

Revenue, yearly change 
-14.3%
EPS, yearly change 
–
FCF, yearly change 
-34.4%
Revenue, average a year 
-10.5%
EPS, average a year 
-2.6%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$167M
Total debt 
$277M
Of which operating leases 
$66M
Net debt 
$45M
Net debt / EBITDA 
1.8x
Interest cover 
-1.8x
Current ratio 
2.04

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 3.5%
5.99%
Buybacks 
10.33%
Total returned 
16.32%
Shares, yearly change 
-3.2%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 51).

Gross margin

69.5%

Above 93% of the 36 companies in its industry, and 86% of all.

Operating margin

4.4%

Above 78% of the 38 companies in its industry, and 48% of all.

Net margin

10.8%

Above 96% of the 39 companies in its industry, and 67% of all.

ROE

19.9%

Above 90% of the 26 companies in its industry, and 84% of all.

ROA

11.4%

Above 96% of the 38 companies in its industry, and 90% of all.

Revenue growth

-14.3%

Above 9% of the 39 companies in its industry, and 7% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
NU SKIN ENTERPRISES, INC.
CIK
1021561
Exchange
NYSE
Industry (SIC)
5122 · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
48.13M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Nu Skin Enterprises's filings show?

These are Nu Skin Enterprises's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NUS

Didn't find what you were looking for?

Ask us
What is NUS's market cap?

Nu Skin Enterprises, Inc.'s market cap is $194M, at a price of $4.03 on November 13, 2026 and 48.13M shares.

How much revenue does NUS have?

Nu Skin Enterprises had revenue of $1.3B over the last 12 months. Over the last 5 years it changed by -10.5% a year on average.

Does NUS pay a dividend?

Yes. Nu Skin Enterprises paid $0.24 per share over the last 12 months, a yield of 5.99% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Nu Skin Enterprises, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.